EAU 2019: Testosterone Slows Recurrence in Patients With PCa

EAU 2019: Testosterone Slows Recurrence in Patients With PCa

Nieprzeczytany postautor: wiatger » 24 mar 2019, 18:31

Na tego rocznym kongresie the European Association of Urology (EAU) w Barcelonie zostało przedstawione dosyć sensacyjne doniesienie naukowe:

EAU 2019: Testosterone Slows Recurrence in Patients With Low-Risk Prostate Cancer

Published in Advanced Prostate Cancer March 21, 2019

Thomas Ahlering, MD, of the University of California, Irvine, noted that this finding was surprising because it was not the initial topic of investigation. Testosterone replacement did not increase recurrence, and in fact, it lowered recurrence rates.
According to Dr. Ahlering, the testosterone is not curing the cancer, but is slowing its growth, resulting in an average of 1.5 additional years before cancer can be detected. This is an additional benefit of testosterone, which is known to improve muscle mass, cholesterol and triglyceride levels, and sexual activity.
Dr. Ahlering noted that this is the largest study to suggest that testosterone may not be dangerous for select patients. Although changes to treatment methods are not currently suggested, the taboo against the use of testosterone in low-risk patients following radical prostatectomy should be questioned.

The oncology/urology community should consider reviewing the use of testosterone.
Testosterone has long been regarded testosterone as promoting prostate cancer. The dramatic impact of testosterone reduction on prostate cancer was first reported in 1941. Since then, anti-testosterone therapy has become a standard option for a vast number of patients.
In the late 1990s to 2000s, it was discovered that though men on long term anti-testosterone treatments were not dying from prostate cancer, they were dying prematurely of cardiovascular disease.
It seemed that, though anti-testosterone therapies were treating prostate cancer, extremely low testosterone levels were worsening metabolic complications such as elevated blood sugar, diabetes, elevated cholesterol, and mid-abdomen visceral fat significantly.
Low testosterone also caused a loss of sexual function in many men receiving anti-androgen treatment. This led to the suggestion of testosterone treatment in some low-risk men after radiation or surgery.
In 2008, Dr. Ahlering and colleagues began to carefully select patients for testosterone replacement after robotic radical prostatectomy in hopes of improving their recovery of sexual function.
The team worked with 834 patients undergoing radical prostatectomy. They treated 152 low-risk patients with no evidence of disease with testosterone replacement therapy.
After a median of 3.1 years following surgery, they tested patients for biochemical recurrence, as indicated by measurement of the Prostate Specific Antigen (PSA) levels.

Zawsze podawaj link do źródła. Thnx.

https://www.practiceupdate.com/content/ ... ncer/81090
ur. 1943. Od 2011 (PSA 1,87 ng/ml) leczenie BPH (Omnic Ocas).
02.2015 – PSA 4,12 ng/ml; MRI miednicy: podejrzenie zmiany npl gruczołu krokowego.
10.2016 – tPSA 6,19 ng/ml; fPSA 0,54 ng/ml; DRE: wyczuwalny guzek.
12.2016 – PSA 7,71 ng/ml; mpMRI: ognisko hipointensywne, cechy infiltracji lewych pęcherzyków nasiennych; miednica bez adenopatii- wysokie podejrzenie naciekającego raka stercza, PI-RADS 5. 02.01.2017 biopsja : płat prawy - w jednym z bioptatów mikroognisko raka gruczołowego ; płat lewy - rak gruczołowy, Gleason 8 (4+4). Naciekanie nerwów niewidoczne. Scyntygrafia b. z.,
Od 18.01.17 Flutamid 3x250mg; 02.17 PSA 2,44 ng/ml; 31.01.17 Eligard 22,5 mg;14.02.17 Flutamid stop. 20.03.17 PSA 0,786 ng/ml. 29.03.17 rozpoczęcie TomoTherapy. 05.2017 Eligard 45 mg. 25.05.17 zakończenie RT, PSA 0,184 ng/ml, T 34 ng/dl; 10.17 tPSA 0,02 ng/ml, T 8,5 ng/dl; 11.17 Eligard 22,5; 02.18 PSA <0,01, Diphereline 11,25; 05.18 PSA <0,006, T 5,0 ng/dl, Diphereline 11,25; 08.18 PSA <0,01, T 28 ng/dl (inne lab.), HT STOP!
po 3 m bez HT (11.18) – PSA 0,035 ; T 127; po 6 m bez HT (02.19) – PSA 0,828 ; T 255;
po 7 m bez HT (03.19) – PSA 0,911; T n.b.; po 8 m bez HT (04.19) – PSA 0,873; T 197;
po 9 m bez HT (05.19) - PSA 0,782; T – 189 ; 06.19 - scyntygrafia i SPECT/CT - bez zmian ogniskowych.
Po 11 m bez HT (07.19) - PSA 0,711; T - 216.
Posty: 126
Rejestracja: 11 lis 2016, 12:00
Lokalizacja: okolice Łodzi
Blog: Wyświetl blog (0)

Wróć do Diagnostyka raka prostaty i publikacje medyczne * Prostate Cancer Diagnostics...

Kto jest online

Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 3 gości

logo zenbox